Explore Our Network
Explore MTEC's network of innovators, investors, and research organizations—along with patents and funding opportunities—advancing medical technologies for military and civilian health.

AdhexPharma is an independent contract development and manufacturing organization (CDMO) specializing in oral films and transdermal or topical patches for drug delivery. The company provides comprehensive end-to-end services from feasibility studies and formulation to analytical development, clinical batch production, and commercial manufacturing under cGMP. With expertise in complex dosage forms, handling potent APIs, and meeting global regulatory requirements, AdhexPharma integrates sustainable practices and operates advanced facilities in France and Germany, supporting both large pharmaceutical firms and biotech innovators worldwide.

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Altrazeal Life Sciences Inc. is a specialty medical technology company dedicated to developing and commercializing innovative drug delivery systems. Their mission is to improve patient outcomes by providing comprehensive solutions for patients, providers, and payers. The company is known for its patented Altrazeal® Transforming Powder Dressing, which optimizes the wound healing environment and supports tissue repair.

Amsel Medical Corporation specializes in the development and commercialization of minimally invasive medical devices for trauma, vascular, and general surgical applications. Its core innovation centers on unique temporary and permanent vessel clamping technologies delivered via needle guidance. For trauma, the company is developing a field-deployable precision hemorrhage control solution for combat and civilian non-compressible junctional hemorrhage injuries . The solution can adjust the degree of vessel occlusion and distal perfusion, minimizing the potential consequences of prolonged limb ischemia and "reperfusion injury", and most importantly extends the "golden hour" for safe evacuation. Saving Limbs...Saving Lives.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

The Armed Forces Institute of Regenerative Medicine (AFIRM) , led by the Wake Forest Institute for Regenerative Medicine, is a collaborative effort involving over 30 academic institutions and industry partners. The consortium focuses on advancing regenerative medicine solutions for battlefield injuries, aiming to improve the lives of wounded service members, veterans, and the general public. With a $40 million, five-year award from the Defense Health Agency, AFIRM is dedicated to developing clinical therapies in areas such as craniofacial regeneration, extremity regeneration, genitourinary/lower abdomen, skin and wound healing, on-demand blood, and cellular therapies for trauma.
Astek Diagnostics is a precision diagnostics company focused on revolutionizing the detection and treatment of bacterial infections. Their flagship product, the JIDDU system, offers rapid and accurate diagnostics for urinary tract infections (UTIs) and antibiotic sensitivity within one hour. This innovation aims to improve patient outcomes by reducing complications, healthcare costs, and antimicrobial resistance. Astek is committed to expanding its diagnostic capabilities to include multiple sample types, including urine, cerebrospinal fluid (CSF), effluent, and blood, with a market launch planned for 2025.

ATD Emolda has been delivering innovative solutions for 40 years, specializing in the conversion and manufacturing of components and assemblies for industrial, medical, and pharmaceutical applications. The company has become a thought leader in advanced wound care materials, focusing on developing high-performance polyurethane foams and silicone adhesives.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Auxilium Health, Inc. is dedicated to providing innovative solutions for wound healing, focusing on delivering smarter and more effective care for patients. Their mission is to enhance the healing process, one patient at a time.

AvantGuard has developed a novel broad-spectrum, bio-compatible antiseptic that is proven in in vitro, ex vivo, and in vivo testing to be safe and more effective than topical antibiotics, while also effective as a liquid sterilant or disinfectant. Our compound, Avantamine, can be packaged as a heat-tolerant, long-shelf-life powder in a metal foil packet that dissolves rapidly in potable water to make either a solution or hydrogel. At a high concentration, Avantamine's non-hazardous, non-corrosive solution will sterilize medical equipment in 10 minutes and is safe enough for instruments to be removed and used without rinsing. Diluted by half, Avant24 at 0.6% concentration is (1) an antiseptic for washing wounds or treating cutaneous bacterial and fungal infections, (2) a high-level disinfectant for a variety of medical devices without corroding metals or degrading plastics, and (3) a disinfectant for surfaces in the surgical suite. At 6X further dilution, Avant24 can treat trench mouth. At another 3X dilution, Avant24 can be added to water to make it drinkable. There are an enormous number of potential uses and the only difference between them is the amount of diluent, in this case water, used to prepare the solution. Our military focus areas are (1) low resource sterilization of medial devices, (2) fungal treatment for burn wounds, and (3) a prophylactic for infection control in a self-administered Role 1 environment with the powder applied directly to a wound. Our commercial focus area is Candida auris decolonization which is not currently possible with any other antiseptic. We have definitive animal testing to show efficacy and superiority to chlorhexidine and are moving toward the clinic.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

BioAesthetics Corporation is working to transform lives through advancements in biomaterials. It is focused on developing life-enhancing/restoring product to improve the outcomes of reconstructive surgeries.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite regenerative implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants, launching in orthopedics/tendons and ligaments. The company driven by a team of visionary entrepreneurs and leading bioscientists and engineers.

Case Western Reserve University is dedicated to solving the biggest issues of today and tomorrow through innovative research and education. With a commitment to experiential learning, the university offers a wide range of programs and opportunities for students to engage in research, internships, and community service, all within a vibrant campus located in Cleveland, Ohio.

Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.

CellBios is a biotechnology company specializing in the design, development, and manufacturing of single-use bioprocessing and medical device solutions for healthcare, biotechnology, and regenerative medicine sectors. The company operates GMP and ISO-certified cleanroom facilities, offering a comprehensive portfolio of cryopreservation products, bioreactors, fluid management systems, advanced packaging, and specialty devices. By leveraging expertise in extrusion, molding, assembly, sterilization, quality control, and regulatory compliance, CellBios provides customized, scalable solutions to support cell and gene therapy, biologics manufacturing, and clinical workflows.

Ceria Therapeutics is a privately held biotechnology company focused on developing novel RNA-based drug products for the treatment of acute and chronic inflammatory diseases. The company aims to address high unmet medical needs by targeting the root causes of dysregulated inflammation, thereby restoring natural healing processes and improving patient outcomes. Its core technology leverages nanoparticle delivery of microRNA therapeutics to modulate inflammatory pathways. Ceria operates research and development facilities in Tucson, Arizona and Aurora, Colorado, and collaborates with leading academic and clinical partners to advance preclinical and clinical programs for conditions such as acute lung injury, diabetic foot ulcers, and inflammatory bowel disease.

Clean Beam Technologies, LLC is dedicated to revolutionizing wound care through innovative technology. Their mission is to provide safe and effective solutions that enhance patient outcomes and improve healthcare practices, particularly focusing on wound sterilization using safe Far UVC light.